- Global Pharma News & Resources

ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 21st tranche of investment today

Amsterdam, The Netherlands - 29 August 2018

Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 21 st Tranche of EUR 300,000 is issued as a private placement of 30 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 485,611 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the "Agreement").  Prior to the issuance of the 21 st Tranche, EUR 7,250,000 of Notes out of the total commitment of EUR 9 million under the Agreement have been issued to the Investor and EUR 247,500 share subscription warrants have been exercised by the Investor.

As of today, the integrality of the EUR 7,250,000 of Notes issued to the Investor since March 8, 2017 under the Agreement have been converted into 17,719,000 shares. The total number of shares outstanding as of today amounts to 34,782,691.
The Notes and the Warrants shall have the same characteristics as those described in the Group's press release dated 8 March 2017.


ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar:  +31 575 548 998  -  or visit the websites at and .


This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).

With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.
This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Esperite in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), it being specified that the securities of Esperite have not been and will not be registered within the US Securities Act. Esperite does not intend to register securities or conduct a public offering in the United States of America.

21st Tranche

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Esperite N.V. via GlobeNewswire

Editor Details

Last Updated: 30-Aug-2018